Live tape
Top 8, mentions 7d30,186NVDA14,245 mentions▲ +0.04ANT4,318 mentions▲ +0.07GOOGL3,145 mentions▲ +0.04SPY2,361 mentions▲ +0.05QQQ1,869 mentions▲ +0.04SPCX1,604 mentions▲ +0.07AMD1,387 mentions▲ +0.06AAPL1,257 mentions▲ +0.04

Equity · Healthcare

JAZZ

NASDAQ

Jazz Pharmaceuticals (JAZZ)

230.57 USD −2.44% vs prior close Nov 20, 2026
Jazz Pharmaceuticals plc price graph
64 sessions
280 200 24 Aug 20 Nov

The line runs 254 USD on 24 August through 230.57 USD on 20 November, on a scale from 200 to 280. Days the market did not trade hold the previous close, flat.

Market cap
14.8B USD
P/E (TTM)
75.1
Revenue, year to Dec 2025
4.3B USD
EPS, diluted, year to Dec 2025
−5.84 USD
52-week range
141 USD – 262 USD
Avg volume
55.8K
Mentions, 30 days
16
Net sentiment
+0.01

as of Nov 20, 2026

Have Jazz Pharmaceuticals (JAZZ) insiders bought or sold shares recently?

In the 90 days to 23 Nov 2026, Jazz Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 26 Feb 2026, show no open-market purchase.

Form 4, 90 days to 23 Nov 2026, newest reported trade 6 Nov 2026

0buys
10sells
$41.42Mnet sold
16other filings
Have Jazz Pharmaceuticals (JAZZ) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
06 Nov 2026COZADD BRUCE CDirectorSell68,80816.2M USD
04 Nov 2026Carr PatriciaSVP, Chief Accounting OfficerSell1,413327K USD
03 Nov 2026GALA RENEE DPresident & CEOSell1,000225K USD
02 Nov 2026COZADD BRUCE CDirectorSell6,0001.3M USD
06 Oct 2026GALA RENEE DPresident & CEOSell2,000473K USD
01 Oct 2026COZADD BRUCE CDirectorSell6,0001.4M USD
10 Sep 2026Patil Neena MEVP & Chief Legal OfficerSell1,200289K USD
08 Sep 2026GALA RENEE DPresident & CEOSell2,000486K USD
01 Sep 2026COZADD BRUCE CDirectorSell6,0001.5M USD
27 Aug 2026Iannone RobertEVP, Global Head of R&D & CMOSell76,92119.2M USD
Sold10 open-market sales171,342$41.42M
16 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Jazz Pharmaceuticals (JAZZ) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
06 Nov 2026COZADD BRUCE CDirectorOption exercise86,50011.8M USD
04 Nov 2026Carr PatriciaSVP, Chief Accounting OfficerOption exercise1,250175K USD
08 Sep 2026Henderson Mary ElizabethSVP, Technical OperationsTax withheld1,427347K USD
08 Sep 2026GALA RENEE DPresident & CEOTax withheld1,967485K USD
31 Aug 2026Kennedy PatrickDirectorTax withheld1,855448K USD
31 Aug 2026Henderson Mary ElizabethSVP, Technical OperationsTax withheld2,092505K USD
31 Aug 2026Smith Mark DouglasDirectorTax withheld1,706412K USD
31 Aug 2026Cook Jennifer E.DirectorTax withheld1,706412K USD
31 Aug 2026Hamill LauraDirectorTax withheld1,706412K USD
31 Aug 2026McSharry Heather AnnDirectorTax withheld1,855448K USD
31 Aug 2026Winningham Rick EDirectorTax withheld1,706412K USD
31 Aug 2026ENRIGHT PATRICK GDirectorTax withheld1,706412K USD

Showing the 12 most recent of 16 compensation filings in this window. The figures above count all of them.

Which funds hold Jazz Pharmaceuticals (JAZZ)?

9 of the 45 institutional funds we track reported a Jazz Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 916.6M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Jazz Pharmaceuticals (JAZZ)?
FundPositionSharesValueShares q/q
AQR Capital ManagementHeld (±25%)1,173,813271.0M USD−22.9%
Citadel AdvisorsHeld (±25%)1,072,736248.4M USD+6.6%
Two Sigma InvestmentsAdded702,217162.6M USD+75.5%
Renaissance TechnologiesHeld (±25%)483,573112.0M USD−14.0%
Man GroupHeld (±25%)166,25338.5M USD+8.7%
Millennium ManagementTrimmed164,25938.0M USD−78.5%
Bridgewater AssociatesNew position145,15533.6M USD
D. E. Shaw & Co.Trimmed28,6006.6M USD−67.2%
Marshall WaceTrimmed25,5175.9M USD−26.7%
Balyasny Asset ManagementExited

Have members of Congress traded Jazz Pharmaceuticals (JAZZ)?

The most recent congressional trade disclosed in Jazz Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 12 Jul 2023.

STOCK Act disclosures

Have members of Congress traded Jazz Pharmaceuticals (JAZZ)?
TradedMemberTypeAmountFiled after
12 Jul 2023Daniel S. Goldmanhouse · Democrat–NYSale15K USD–50K USD32 days
06 Mar 2023Daniel S. Goldmanhouse · Democrat–NYPurchase15K USD–50K USD42 days
31 Jan 2023Daniel S. Goldmanhouse · Democrat–NYSale1K USD–15K USD24 days
19 Oct 2021Thomas R. Suozzihouse · Democrat–NYPurchase1K USD–15K USD17 days

What has been filed or recorded for Jazz Pharmaceuticals (JAZZ)?

The filings we hold for Jazz Pharmaceuticals, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 27 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Jazz Pharmaceuticals (JAZZ)?
And
27 Oct 2026Fails to deliverShares failed to deliver574 shares118K USD notional · 0.001% of shares out
23 Oct 2026Fails to deliverShares failed to deliver3,610 shares775K USD notional · 0.006% of shares out
21 Oct 2026Fails to deliverShares failed to deliver199 shares43K USD notional · <0.001% of shares out
14 Oct 2026Fails to deliverShares failed to deliver2,115 shares445K USD notional · 0.003% of shares out
09 Oct 2026Fails to deliverShares failed to deliver102 shares23K USD notional · <0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver6 shares1K USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −7.48 USD
30 Sep 2026FinancialsTotal assets12.0B USDat period end
30 Sep 2026FinancialsTotal equity4.2B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 2.78 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 4.43 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −5.84 USD
31 Dec 2025FinancialsRevenue4.3B USDfiscal year
31 Dec 2025FinancialsNet income−356.1M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−5.84 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 4.08 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −11.74 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −1.52 USD
31 Dec 2024Annual reportFY 2024 reportedEPS 8.65 USD

What is Reddit saying about Jazz Pharmaceuticals (JAZZ)?

Reddit mentioned JAZZ 16 times in the 30 days to 22 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 56% read bullish, 19% bearish and 25% neither. Reddit data updated 22 November 2026.

30-day window, Method

16mentions, 30 days
56%bullish
19%bearish
2communities
+4pointsagainst the market

How do Reddit mentions of Jazz Pharmaceuticals (JAZZ) compare with its price?

Share ↗
16 mentions

Which subreddits are talking about Jazz Pharmaceuticals (JAZZ)?

30 days

Which subreddits are talking about Jazz Pharmaceuticals (JAZZ)?
CommunityShareMentionsNet sentiment
r/wallstreetbets63%10−0.04
r/ausfinance38%6+0.10

Which names move with Jazz Pharmaceuticals (JAZZ) on Reddit?

6 names, 30 days

DOLE moved most closely with Jazz Pharmaceuticals (JAZZ): when the crowd talked about one, it talked about the other (+0.69 over 31 days). Co-discussion, not price.

How closely JAZZ's daily Reddit mentions moved with each name, 30 days
BRY
JAZZ
+0.69+0.68+0.66+0.65+0.65+0.62
View the matrix as a tableHide the table
Names that move with JAZZ on Reddit, 30 days
PairMatchDays measured
JAZZ and DOLE+0.6931 days
JAZZ and FEAT+0.6831 days
JAZZ and BRY+0.6631 days
JAZZ and SCI+0.6531 days
JAZZ and ESP+0.6531 days
JAZZ and BITS+0.6231 days

What do people ask about Jazz Pharmaceuticals (JAZZ)?

From live data
What did Jazz Pharmaceuticals shares close at?230.57

Jazz Pharmaceuticals closed at 230.57 USD on 20 Nov 2026, down 2.44% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Jazz Pharmaceuticals’ market cap?14.8B

Jazz Pharmaceuticals is worth 14.8B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Jazz Pharmaceuticals’ P/E ratio?75.1

Jazz Pharmaceuticals has a price-to-earnings ratio of 75.1, as of 20 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

What is Jazz Pharmaceuticals’ revenue?4.3B

Jazz Pharmaceuticals reported revenue of 4.3B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Jazz Pharmaceuticals insiders bought or sold shares recently?10 sales

In the 90 days to 23 Nov 2026, Jazz Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 26 Feb 2026, show no open-market purchase. A further 16 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Jazz Pharmaceuticals?9 of 45

9 of the 45 funds we track reported a Jazz Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Citadel Advisors and Two Sigma Investments. See Funds

Have members of Congress traded Jazz Pharmaceuticals?4 trades

Yes. 4 trades in Jazz Pharmaceuticals appear in the congressional disclosures we hold; the latest is a sale by Daniel S. Goldman (House, NY) dated 12 Jul 2023, filed 13 Aug 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Jazz Pharmaceuticals last report earnings?−7.48

Jazz Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −7.48 USD; no next date is announced in SEC filings yet. See Filings

What is Reddit saying about Jazz Pharmaceuticals?0 mentions

Jazz Pharmaceuticals was mentioned 0 times in the last 7 days across the finance subreddits we track, and 16 times over the trailing 30 days. Of the 16 mentions scored for sentiment, 56% read bullish and 19% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. RedditReddit ingest across the tracked finance subreddits
  4. SEC EDGARForm 4 filings (insider transactions)
  5. SEC EDGAR13F filings
  6. Wikimedia CommonsPortraits via Wikimedia Commons. Daniel S. Goldman: US House, Public domain; Thomas R. Suozzi: Österreichisches Außenministerium (BMEIA/ Michael Gruber), CC BY 4.0.
  7. House disclosuresU.S. House of Representatives financial disclosures
  8. SECSEC fails-to-deliver (CNS) data
  9. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  10. SEC EDGARreported earnings figures and scheduled report dates
  11. SEC EDGARValuation computed from SEC EDGAR filings
  12. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words